Create Account | Sign In: Author or Forum

 
News  |  Journals  |  Conferences  |  Opinion  |  Articles  |  Forums  |  Twitter    
 
Category: Internal Medicine | Ophthalmology | Pediatrics | Journal

Back to Journal Articles

Gene Therapy Shows Promise in Inherited Sight Disorder

Last Updated: October 26, 2009.

 

Treatment much more effective in children, allowing them to walk without help

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
Gene therapy for a rare inherited sight disorder in which severely impaired vision in childhood usually results in blindness in adulthood can substantially improve vision, particularly in children, according to a study published online Oct. 24 in The Lancet.

MONDAY, Oct. 26 (HealthDay News) -- Gene therapy for a rare inherited sight disorder in which severely impaired vision in childhood usually results in blindness in adulthood can substantially improve vision, particularly in children, according to a study published online Oct. 24 in The Lancet.

As part of a Phase I trial, Albert M. Maguire, M.D., from the University of Pennsylvania in Philadelphia, and colleagues treated 12 patients with incurable inherited retinal degeneration due to Leber's congenital amaurosis with a single subretinal injection in the worst eye of a virus carrying the RPE65 gene, which is mutated in the disease and encodes a protein needed for the isomerohydrolase activity of the retinal pigment epithelium. The disease has been traced to mutations in any of 13 genes, and this particular mutation accounts for about 6 percent of cases, they note.

The researchers found that the virus was well tolerated and led to sustained improvements in five subjective and objective measures of vision. Patients also showed an increase of at least 100-fold in pupillary light responses. Children (aged 8 to 11 years) improved the most, with all gaining ambulatory vision allowing them to walk unaided even in dim light.

The study "will further boost gene therapy trials and provide hope for patients with inherited blindness and other genetic disorders," write the authors of an accompanying editorial. "As novel therapeutic strategies are being developed for each of the separate genetic defects, ascertaining and genotyping the corresponding patients will be the real challenge in the coming decade."

Several authors reported financial and consulting relationships with drug companies, although this often did not involve retinal research. Two authors are co-inventors of a pending patent for a method to treat or slow the development of blindness, but have waived any financial interest in the technology.

Abstract
Full Text (subscription or payment may be required)
Comment (subscription or payment may be required)

Copyright © 2009 ScoutNews, LLC. All rights reserved.


Previous: Low-Dose Regimen Found to Improve Myeloma Survival Next: Protein Linked to Development of Some Lung Cancers

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2014
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.